Immunological control of beta-amyloid levels in vivo
AssigneeBoston Biomedical Research Institute
InventorVictor Raso
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a predetermined amide linkage are provided. The present invention also provides a vectorized antibody that is capable of crossing the blood brain barrier and is also capable of catalyzing the hydrolysis of β-amyloid at a predetermined amide linkage. Also provided are methods for modulating β-amyloid levels in vivo using antibodies that bind to β-amyloid. These compositions and methods have therapeutic applications, including the treatment of Alzheimer's disease.
Claims11
1-36. (canceled)
A method of sequestering amyloid β (Aβ) peptides in the bloodstream of a human patient diagnosed with or at risk of developing Alzheimer's disease, comprising:
- administering to the human patient an antibody that binds to a human Aβ peptide in a regime effective to sequester Aβ peptides in the bloodstream of the human patient.
A method of sequestering amyloid β (Aβ) peptides in the bloodstream of a human patient diagnosed with or at risk of developing Alzheimer's disease, comprising:
- administering to the human patient a human Aβ peptide comprising an epitope within the N-terminal region of human Aβ1-43 and an adjuvant in a regime effective to sequester Aβ peptides in the bloodstream of the human patient.
Dependencies are inferred from the claim text.